Ultragenyx Pharmaceutical Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated June 19, 2018, details the results of Ultragenyx Pharmaceutical Inc.'s Annual Meeting of Stockholders. The meeting was held on June 19, 2018, with a record date of April 23, 2018. As of the record date, 49,705,310 shares of common stock were outstanding, with 45,889,732 shares represented at the meeting.
Key Financial Metrics
This filing is a corporate governance report regarding stockholder votes and does not contain financial performance data. The filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Voting Results
The filing reports the outcomes of three proposals submitted to stockholders:
- Proposal 1: Election of Class II Directors
- Deborah Dunsire, M.D.: Elected with 44,095,709 votes for, 41,275 withheld.
- Michael Narachi: Elected with 43,694,124 votes for, 442,860 withheld.
- Clay B. Siegall, Ph.D.: Elected with 41,821,327 votes for, 2,315,657 withheld.
- Proposal 2: Ratification of Independent Auditor
- Stockholders ratified the selection of Ernst & Young LLP for the fiscal year ending December 31, 2018.
- Results: 45,819,251 votes for, 63,255 against, 7,226 abstentions.
- Proposal 3: Advisory Vote on Executive Compensation
- Stockholders voted in favor of the advisory resolution approving executive compensation.
- Results: 32,906,051 votes for, 11,223,276 against, 7,657 abstentions.
Guidance, Outlook, and Risks
This filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It is strictly a report of the voting results from the Annual Meeting.
Key Facts for Investor Verification
- Verify the tenure of the newly elected Class II directors, who will serve until the 2021 Annual Meeting.
- Note the significant number of votes against the executive compensation proposal (11.2 million), which may indicate shareholder sentiment regarding pay practices.
- Confirm the continued engagement of Ernst & Young LLP as the independent auditor for the 2018 fiscal year.
- Review the full Proxy Statement for detailed context on the executive compensation package that received a mixed vote.